Literature DB >> 26637479

Functional Studies on Viable Circulating Tumor Cells.

Klaus Pantel1, Catherine Alix-Panabières2.   

Abstract

BACKGROUND: Research on circulating tumor cells (CTCs) as new biomarkers has received great attention over the past decade. In particular, the capture and analysis of CTCs as "liquid biopsies" provides the possibility to avoid invasive tissue biopsies, with obvious implications in cancer diagnostics. CONTENT: The focus of this review is to describe and discuss how functional studies on viable CTCs can enlarge the spectrum of applications of liquid biopsies, with emphasis on breast, prostate, colon, and lung cancer as the major tumor entities in industrialized countries. The low number of CTCs in the peripheral blood of most cancer patients makes challenging the in vitro culture of CTCs. Epithelial tumor cells are difficult to culture, even when starting with millions of tumor cells. Recently, several groups have achieved important advances in the in vitro and in vivo expansion of CTCs from cancer patients at very advanced stages with higher amounts of CTCs. Here, we present current technologies to enrich and detect viable human CTCs, including positive and negative enrichment strategies that are based on antigen expression and physical properties of CTCs. We also discuss published data about functional studies on CTCs that use in vitro and in vivo models.
SUMMARY: Functional analyses on CTCs offer the possibility to identify the biological properties of metastatic cells, including the identification of metastasis-initiating cells. Moreover, CTC-derived cell lines and xenografts might reveal new therapeutic targets and can be used for drug screening.
© 2015 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26637479     DOI: 10.1373/clinchem.2015.242537

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  36 in total

1.  Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers.

Authors:  Vasudha Murlidhar; Rishindra M Reddy; Shamileh Fouladdel; Lili Zhao; Martin K Ishikawa; Svetlana Grabauskiene; Zhuo Zhang; Jules Lin; Andrew C Chang; Philip Carrott; William R Lynch; Mark B Orringer; Chandan Kumar-Sinha; Nallasivam Palanisamy; David G Beer; Max S Wicha; Nithya Ramnath; Ebrahim Azizi; Sunitha Nagrath
Journal:  Cancer Res       Date:  2017-07-17       Impact factor: 12.701

2.  Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems.

Authors:  Christof Bernemann; Julie Steinestel; Martin Boegemann; Andres J Schrader
Journal:  World J Urol       Date:  2017-02-28       Impact factor: 4.226

3.  Technical Insights into Highly Sensitive Isolation and Molecular Characterization of Fixed and Live Circulating Tumor Cells for Early Detection of Tumor Invasion.

Authors:  Sophie Laget; Lucile Broncy; Katia Hormigos; Dalia M Dhingra; Fatima BenMohamed; Thierry Capiod; Magne Osteras; Laurent Farinelli; Stephen Jackson; Patrizia Paterlini-Bréchot
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

Review 4.  Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring.

Authors:  David Pérez-Callejo; Atocha Romero; Mariano Provencio; María Torrente
Journal:  Transl Lung Cancer Res       Date:  2016-10

5.  Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma.

Authors:  Marika Sciandra; Alessandra De Feo; Alessandro Parra; Lorena Landuzzi; Pier-Luigi Lollini; Maria Cristina Manara; Gianfranco Mattia; Giada Pontecorvi; Cristina Baricordi; Clara Guerzoni; Alberto Bazzocchi; Alessandra Longhi; Katia Scotlandi
Journal:  J Cell Commun Signal       Date:  2020-06-05       Impact factor: 5.782

Review 6.  Pathologists and liquid biopsies: to be or not to be?

Authors:  Paul Hofman; Helmut H Popper
Journal:  Virchows Arch       Date:  2016-08-23       Impact factor: 4.064

7.  High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients.

Authors:  Yin Tang; Zhuo Wang; Ziming Li; Jungwoo Kim; Yuliang Deng; Yan Li; James R Heath; Wei Wei; Shun Lu; Qihui Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

Review 8.  Cell Lines of Circulating Tumor Cells: What Is Known and What Needs to Be Resolved.

Authors:  Yutaka Shimada; Tetsuo Sudo; Shusuke Akamatsu; Takuro Sunada; Akira Myomoto; Kiyoshi Okano; Kazuharu Shimizu
Journal:  J Pers Med       Date:  2022-04-21

Review 9.  [Current progress in research of circulating tumor cells].

Authors:  Qian-Wen Zhao; Bo Situ; Lei Zheng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-10-20

10.  3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade.

Authors:  Amir R Aref; Marco Campisi; Elena Ivanova; Andrew Portell; Dalia Larios; Brandon P Piel; Natasha Mathur; Chensheng Zhou; Raven Vlahos Coakley; Alan Bartels; Michaela Bowden; Zach Herbert; Sarah Hill; Sean Gilhooley; Jacob Carter; Israel Cañadas; Tran C Thai; Shunsuke Kitajima; Valeria Chiono; Cloud P Paweletz; David A Barbie; Roger D Kamm; Russell W Jenkins
Journal:  Lab Chip       Date:  2018-10-09       Impact factor: 6.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.